




The relative strengths and weaknesses of Nurix Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nurix Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 103% points. The greatest weakness of Nurix Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 314%, being 85% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	606,819
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	86,471
Liabilities, Non-Current	62,917
Other Assets	58,826
Other Compr. Net Income	-45
Other Expenses	760
Other Liabilities	0
Other Net Income	0
Other Revenues	105,949
Property and Equipment	22,490
Research and Development	316,903
Selling, General and Administrative Expense	52,743

Output Variable	Value in 1000 USD
Assets	688,135
Liabilities	149,388
Expenses	370,406
Revenues	105,949
Stockholders Equity	538,747
Net Income	-264,457
Comprehensive Net Income	-264,480
BaseVar	656,962
ECR before LimitedLiability	217%
Economic Capital Ratio	314%